Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Observational study of preoperative nivolumab in high-risk stage I non-small cell lung cancer
jRCT1060190007Active, not recruiting
- Sponsor
- Hiroshima University Hospital
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by Hiroshima University Hospital. Primary endpoint: overall survival. Started Jul 2019; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT1060190007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1060190007.